Xinying Qian

Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer.

Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer.

Journal: Journal of medicinal chemistry

Published: June 05, 2026

NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models.

NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 28, 2026

Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

Journal: European journal of medicinal chemistry

Published: August 15, 2025

Discovery of KBD4466, a Selective TLR 7/8 Inhibitor, for the Treatment of Autoimmune Diseases.

Discovery of KBD4466, a Selective TLR 7/8 Inhibitor, for the Treatment of Autoimmune Diseases.

Journal: Journal of medicinal chemistry

Published: July 01, 2025

Serine starvation suppresses the progression of esophageal cancer by regulating the synthesis of purine nucleotides and NADPH.

Serine starvation suppresses the progression of esophageal cancer by regulating the synthesis of purine nucleotides and NADPH.

Journal: Cancer & metabolism

Published: March 25, 2024

Correction to "Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production".

Correction to "Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production".

Journal: Journal of medicinal chemistry

Published: September 14, 2020

Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production.

Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production.

Journal: Journal of medicinal chemistry

Published: June 05, 2020

Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.

Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: October 21, 2019

Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment.

Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment.

Journal: Oncology reports

Published: October 02, 2019

Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells.

Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells.

Journal: Cell death & disease

Published: August 30, 2019

Corrigendum to "ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway" [Cancer Lett. 454 (2019) 179-190].

Corrigendum to "ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway" [Cancer Lett. 454 (2019) 179-190].

Journal: Cancer letters

Published: May 20, 2019

ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.

ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.

Journal: Cancer letters

Published: November 08, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026